News
-
2025-06-06
GenEditBio Announces First Patient Dosed in Investigator-Initiated Trial of GEB-101, World’s First In Vivo CRISPR-Cas RNP-Based Genome Editing Investigational Therapy for TGFBI Corneal Dystrophy
GenEditBio announced the initiation of the world’s first investigator-initiated trial of GEB-101, an in vivo CRISPR-Cas ribonucleoprotein (RNP)-based genome editing investigational therapy for TGFBI stromal corneal dystrophy. The open-label and dose-escalation study has dosed its first patient, marking a key milestone in precision medicine in ophthalmology.
more >
-
2025-06-04
GenEditBio Co-Founder and Chairman Shares Expert Insights on Therapeutic Genome Editing in Exclusive PharmaBoardroom Interview: The Journey from Technology Innovator to Therapeutic Pioneer
GenEditBio Co-Founder and Chairman, Professor Zongli ZHENG, was featured in an exclusive, in-depth interview with PharmaBoardroom, sharing his scientific journey in therapeutic genome editing and outlining the company’s strategies to provide fundamentally safe, efficacious and affordable in vivo genome editing therapies to treat genetic diseases with unmet needs.
more >
-
2025-05-16
GenEditBio Scientist Receives Excellence in Research Award at the 28th Annual Meeting of the American Society of Gene and Cell Therapy 2025
GenEditBio scientist receives Excellence in Research Award for work showcasing the latest preclinical data in non-human primates on an early-stage corneal dystrophy program utilizing our new in vivo delivery technology platform—protein delivery vehicle (PDV).
more >
Copyright © 2025 GenEditBio
Provide affordable precision DNA surgery for genetic diseases with unmet needs
Business Contact bd@geneditbio.com
Media Contact geb.media@geneditbio.com
HONG KONG Unit 101-102, Building 6W, 6 Science Park West Avenue, Hong Kong hkoffice@geneditbio.com
BEIJING 4/F, Building 29, Yard 18, Kechuang 13th St, VPark, Beijing
